BPMC News and Press, Blueprint Medicines Corporation From 06/18/21

Halvorsen's 13F portfolio value decreased from $36.37B to $33.58B. The number of positions decreased from 96 to 94. Viking Global added Bank of America while reducing JPMorgan Chase and dropping Walt Disney. The top three positions are Microsoft, BridgeBio Pharma, and Fidelity Nat...

FDA Approves Blueprint Medicines' AYVAKIT™ (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis -- First precision therapy that specifically targets the primary driver of the disease -- -- Durable clinical responses, including complete remissi...

Lone Pine Capital’s 13F portfolio value increased marginally from $27.51B to $27.53B. The number of positions decreased from 41 to 38. They increased Facebook, Microsoft, and DoorDash while dropping DocuSign, Autodesk, and Humana. The top three positions are Shopify, Micros...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Satu...

ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...

Blueprint Medicines Presents ARROW Trial Data for GAVRETO® (pralsetinib) Highlighting Durable Clinical Activity in Patients with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer and Other Advanced Solid Tumors -- 88% ORR and median duration of response not reached ...

Blueprint Medicines (BPMC) announces the appointment of Percy Carter as the company's chief scientific officer, effective May 19, 2021.Carter brings more than 20 years of pharmaceutical company and industry experience, and prior to joining Blueprint, he served as chief sci...

Blueprint Medicines Appoints Percy Carter, MBA, Ph.D., as Chief Scientific Officer PR Newswire CAMBRIDGE, Mass. , May 17, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of Percy Carter , MBA, Ph.D., as...

CANbridge will make a $10 million upfront payment for the two Fabry and Pompe candidates. Guangzhou Link Health Pharma and Australia's George Clinical plan to form a China clinical CRO JV that will conduct trials for Link Health's in-licensed portfolio. Discovered by CStone's part...